Hydromorphone Hydrochloride Tablet, Extended Release
Product Images NDC 13811-704

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Hydromorphone Hydrochloride (NDC 13811-704). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Trigen Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Hydromorphone Hydrochloride Extended Release Table 1)

This is a list of various types of oral opiates and their corresponding dosage strengths. The opiates included are hydromorphone, codeine, hydrocodone, methadone, morphine, oxycodone, and oxymorphone.*

FDA Label Image

Hydromorphone Hydrochloride Extended Release Table 10

FDA Label Image

Hydromorphone Hydrochloride Extended Release Table 11

This is a medication guide for Hydrocodone Hydrochloride Extended-release Tablets. It is important to take the tablets whole without breaking, crushing, or chewing them. Each tablet contains 8 mg of the active ingredient. The recommended dosage should be obtained from the package insert. The medication should be kept out of reach of children and stored at room temperature. Dispensing should be done in a well-closed container with a child-resistant closure. This medication is for opioid-tolerant patients and should only be prescribed by a doctor. The package contains 100 tablets, and the medication guide should be provided to each patient separately.*

FDA Label Image

Hydromorphone Hydrochloride Extended Release Table 12

This is a medication warning label for extended-release tablets containing Hydromorphone Hydrochloride USP. The label advises to swallow the tablets whole, without breaking, crushing or chewing them, and to follow the package insert for dosage information. The medication is known to be harmful to children and the label instructs to store it out of their reach at controlled room temperature. The label also specifies the manufacturer, Trigen Laboratories LLC, and provides a unique product identification number. Finally, the label recommends dispensing the medication guide to each patient separately.*

FDA Label Image

Hydromorphone Hydrochloride Extended Release Table 13

This is a medication label for Hydrochloride extended-release tablets containing 16mg Hydromorphone Hydrochloride. The tablets must be swallowed whole and should not be crushed or chewed. Dosage information must be obtained from the package insert. The medication is to be kept out of reach of children in a well-closed container. It is manufactured by Trigen Laboratories and dispensed with a child-resistant closure by the pharmacist. The medication guide must be provided separately to each patient. The label further specifies storage conditions, the manufacturer's website, and other relevant information.*

FDA Label Image

Hydromorphone Hydrochloride Extended Release Table 14

Each tablet of Hydromorphone Hydrochloride USP contains 32mg, and it's recommended to swallow the tablet whole without crushing or chewing it. This medication should only be taken by opioid-tolerant patients, and the package insert should be consulted for dosage information. It is crucial to keep out of reach of children and store it at a temperature of 20°-25°C (68°-77°F). The medication should be dispensed in a well-closed container with child-resistant closure, and the medication guide that has been provided should be dispensed separately to each patient. For more information, visit the Trigen Laboratories website.*

FDA Label Image

Figure 1 (Hydromorphone Hydrochloride Extended Release Table 2)

This appears to be a table showing the results of a clinical trial for the medication Hydromorphone in Extended-Release Tablet form for the treatment of various symptoms such as constipation, nausea, somnolence, headache, vomiting, pruritus, dizziness, insomnia, dry mouth, edema peripheral, hyperhidrosis, arthralgia, abdominal pain, muscle spasms and weight decreased during Open-Label Titration Phase and Double-Blind Treatment Phase.*

FDA Label Image

Figure 2 (Hydromorphone Hydrochloride Extended Release Table 3)

The text provides a table showing the number of patients (out of 2,474) experiencing different symptoms while on a certain treatment or in a clinical trial. The symptoms listed include constipation, nausea, vomiting, somnolence, headache, asthenia/fatigue, dizziness, diarrhea, pruritus, insomnia, hyperhidrosis, peripheral edema, anorexia/decreased appetite, dry mouth, abdominal pain, anxiety, back pain, dyspepsia, depression, dyspnea, muscle spasms, arthralgia, rash, pain in extremity, pain, drug withdrawal syndrome, pyrexia, fall, and chest pain.*

FDA Label Image

Trigen Logo (Hydromorphone Hydrochloride Extended Release Table 4)

FDA Label Image

Hydro8mg (Hydromorphone Hydrochloride Extended Release Table 5)

This appears to be a graph or figure showing the steady-state plasma concentration profile of hydromorphone, a medication used for pain relief. The graph shows the concentration of the drug in ng/mL over time (in hours) for a specific dose (16mg) and formulation (Hydromorphone ERT) as well as an MR (Modified Release) formulation with 4mg.*

FDA Label Image

Hydro12mg (Hydromorphone Hydrochloride Extended Release Table 6)

FDA Label Image

Hydro16mg (Hydromorphone Hydrochloride Extended Release Table 7)

This is a figure showing the percentage of improvement or reduction in average pain intensity of patients from screening to week 12 or final visit. The graph compares the effectiveness of Hydromorphones ERT and Placebo in reducing pain. Thus, it is a visual representation of the pain management outcomes of a clinical study.*

FDA Label Image

Hydro32mg (Hydromorphone Hydrochloride Extended Release Table 8)

This is a list of tablets with different strengths, colors, and descriptions. Each bottle contains 100 tablets and has a unique NDC number. The tablets are round, biconvex, and printed with numbers: "0S 211" for 8mg tablet, "0S 212" for 12mg tablet, "OS 213" for 16mg tablet, and "OS 214" for 32mg tablet.*

FDA Label Image

Hydromorphone Hydrochloride Extended Release Table 9

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.